What's new

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

May 19, 2025 - 16:15
 0
Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Beovu, brolucizumab, D...

Next Article

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab,...

Related Posts

PSUSA/00001606/202409

PSUSA/00001606/202409

May 13, 2025  0

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

May 16, 2025  0

Records of data processing activity for the Organisatio...

May 19, 2025  0